It was reported that IL-9 could promote the survival and drug resistance of cells in patients with DLBCL, while silencing of IL-9R gene could reduce IL-9-induced drug resistance, and thus, IL-9 provides a potential therapeutic target for DLBCL (50). This evidence concerns the gene IL9R and diffuse large B-cell lymphoma.